Johnson & Johnson
Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.
JNJ Key Statistics
Stock Snapshot
Johnson & Johnson(JNJ) stock is priced at $205.60, giving the company a market capitalization of 498.07B. It carries a P/E multiple of 20.01 and pays a dividend yield of 2.5%.
On 2025-12-23, Johnson & Johnson(JNJ) stock moved within a range of $203.28 to $206.55. With shares now at $205.60, the stock is trading +1.1% above its intraday low and -0.5% below the session's peak.
Trading volume for Johnson & Johnson(JNJ) stock has reached 7.05M, versus its average volume of 10.24M.
The stock's 52-week range extends from a low of $140.68 to a high of $215.19.
The stock's 52-week range extends from a low of $140.68 to a high of $215.19.
JNJ News
A Baltimore jury has ordered Johnson & Johnson (JNJ) and its subsidiaries to pay more than $1.5B to a woman who said decades of exposure to asbestos in the comp...
Erik Haas, worldwide VP of litigation, Johnson & Johnson said: “We will immediately appeal this egregious and patently unconstitutional verdict that is the dire...
A Baltimore city jury ordered Johnson & Johnson to pay over $1.5 billion in a lawsuit that alleged the company’s talc-based personal products gave a Maryland wo...
Analyst ratings
56%
of 27 ratingsMore JNJ News
Key Points Coca-Cola has increased its dividend for 63 straight years. Johnson & Johnson has matched Coca-Cola's dividend growth streak. Consolidated Edison...
Johnson & Johnson (JNJ) has quietly climbed about 17% over the past 3 months and roughly 44% year to date, putting the spotlight back on what investors are real...
A Maryland jury ordered Johnson & Johnson (JNJ) to pay about $1.56 billion to a woman who claimed the company’s talc-based baby powder caused her cancer. The ca...
Johnson & Johnson JNJ announced that the FDA has approved the subcutaneous (under the skin or SC) formulation of its EGFR/MET inhibitor, Rybrevant (amivantamab)...
A Baltimore jury on Monday ordered Johnson & Johnson (NYSE:JNJ) and its subsidiaries to pay over $1.5 billion to a woman, who claimed that decades of exposure t...
Wondering if Johnson & Johnson is still a buy at around $206 a share, or if the easy gains are already behind it? This breakdown will help you decide whether th...
Johnson & Johnson (NYSE:JNJ) has been directed to pay $65.6 million to a Minnesota woman who was diagnosed with cancer following the use of their talcum powder....